Global Liver Institute
GLOBAL LIVER INSTITUTE
Global Liver Institute Applauds HRSA’s Announcement of OPTN Modernization Initiative and Contract Break Up as Critical to Achieve Health Equity
Global Liver Institute commends Health Resources and Services Administration (HRSA)’s recent announcement that it will break up the Organ Procurement and Transplantation Network (OPTN) monopoly.
Public Witness Testimony, Donna Cryer
GLI CEO Donna R. Cryer addresses the concerns of the liver disease community about the senseless rising incidence of liver disease and liver cancers when measures to prevent, diagnose, and treat liver disease and liver cancer are available.
New Report Indicates Urgent Global Need for Liver Disease Prevention & Treatment
As part of its Liver Health is Public Health initiative, Global Liver Institute’s (GLI) recent Global State of Liver Health report has exposed alarming trends in liver disease through compiled statistics and expert perspectives.
6th Annual International NASH Day: Step Up for NASH
Let’s Step Up for NASH this June and raise awareness about nonalcoholic fatty liver disease (NAFLD) and its more advanced form, nonalcoholic steatohepatitis (NASH), in your communities.
Let’s Keep Moving the Needle Forward
With the NASH horizon full of new developments, it is important to maintain focus on high-quality, affordable, and equitable care for patients with NAFLD and NASH.
At GLI, we strive to keep you up to date and in-the-know with the latest in the field of liver cancers.
Clinical Care Guidelines & Guidances in NAFLD/NASH
In an effort to manage this growing disease, the AGA, AACE and AASLD developed evidence-based clinical practice guidelines that highlight recommendations for screening, diagnosis and management of NAFLD and NASH.
GLI’s Liver Action Network Emphasizes the Link between NASH and Obesity on World Obesity Day
As members of Global Liver Institute’s Liver Action Network (LAN), the undersigned organizations are proud to take part in World Obesity Day. We recognize the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity.
Advancements in Rare Liver Disease Treatment
Thanks to the dedication of researchers and innovators, patients with several rare liver diseases can find hope in the promise of new treatments on the horizon – great news on the heels of Rare Liver Diseases Month.
Patient Advocacy at Work
February, the rare shortest month of the year, also marks the month for rare liver diseases.
Bringing Hope to Patients
Recent months have been marked with promising advances in the fight against liver cancers for patients around the globe.
A Critical Time in NASH
With NASH drug approval in the US on the horizon, energy has been high throughout the field. Nevertheless, we still face challenges – regulatory science must be aligned, and advocacy among stakeholders must be employed to help patients understand what to expect once we enter this new stage of NASH treatments.